From ASCRS 2026: iDose TR & Interventional Glaucoma (IG) (Part 2) – Featuring Glaukos

Pass-Through Drugs 101: Understanding the Reimbursement, Compliance, and Quality Impact

In Episode 1 of our Summer Series, learn the fundamentals of pass-through status, current ophthalmic examples, coding considerations, financial implications, and how these therapies intersect with MIPS and value-based care. This summer, Ophthalmology Reimbursed is taking a deep dive into one of the most important and often misunderstood areas of ophthalmology reimbursement. Join us for our three-part podcast series:  Beyond the Bundle: Understanding Separate Reimbursement for Drugs, Devices, and Tissues in Ophthalmology As innovation continues to reshape ophthalmic care, practices are navigating increasingly complex reimbursement pathways for drugs, devices, biologics, and tissues that may qualify for separate payment outside traditional bundled reimbursement models. Throughout this series, our consultants will discuss the opportunities, challenges, and compliance considerations surrounding these payment methodologies and how they impact physician practices, ambulatory surgery centers, and hospital outpatient departments.

What the 2026 CPT Panel Actions Mean for Ophthalmology

The CPT Editorial Panel’s February and May 2026 Summary of Actions offers an early look at where coding and reimbursement are headed, and ophthalmology is clearly part of the conversation. In this episode, our consultants break down the ophthalmology-related proposals, accepted actions, withdrawn items, and emerging Category III codes discussed by the CPT Panel. Topics include adult goniotomy coding changes, intraocular drug delivery implants, subretinal prostheses, intracapsular magnification devices, minimally invasive glaucoma procedures, and evolving crosslinking HCPCS reporting. The discussion also explores why Category III codes matter, how CPT Panel actions influence future reimbursement pathways, and what ophthalmology practices should be watching now to prepare for future operational and documentation changes. Contact us by calling (800) 399-6565 or visiting CorcoranCCG. [https://corcoranccg.com/]

From ASCRS 2026: New Frontiers in Eye Care (Part 3) – Featuring Alcon

In Part 3 of our ASCRS 2026 series, we explore photobiomodulation and its potential role in advancing eye care. We’re joined by Traci Brackett and Joshua Anderson from Alcon, who share their insights on this emerging therapy, how it works, and where it may fit into clinical practice. From innovation to real-world application, this conversation highlights what providers should know as new technologies continue to shape the future of patient care. Contact us by calling (800) 399-6565 or visiting CorcoranCCG. [https://corcoranccg.com/]

From ASCRS 2026: iDose TR & Interventional Glaucoma (IG) (Part 2) – Featuring Glaukos

In Part 2 of our ASCRS 2026 coverage, we dive into iDose TR and the evolution of interventional glaucoma. Joined by Tom Powell and Cynthia Pointer from Glaukos, we explore what these innovations mean in practice, how they’re changing treatment approaches, and what providers should be paying attention to moving forward. Contact us by calling (800) 399-6565 or visiting CorcoranCCG. [https://corcoranccg.com/]

From ASCRS 2026: Key Conversations & Insights (Part 1) – Promptly’s Anish Kapur

This is Part 1 of our ASCRS series.  In this episode, we are sharing key highlights and emerging trends discussed at the recent ASCRS/ASOA meeting in Washington, DC. We’re joined by Anish Kapur, who offers his perspective on what’s shaping the industry—grounded in his work with Promptly, a patient engagement platform focused on streamlining payments, collections, and patient communication through automation and AI. Contact us by calling (800) 399-6565 or visiting CorcoranCCG. [https://corcoranccg.com/]